APPLICATION OF PEDIATRIC FLEXIBLE BRONCHOSCOPY IN DIAGNOSIS AND TREATMENT OF RESPIRATORY DISEASES IN VIET NAM NATIONAL CHILDREN’S HOSPITAL
##plugins.themes.vojs.article.main##
Abstract
Objective: Review the treatment outcomes of severe Mycoplasma pneumoniae pneumonia at the Center for pulmonology and respiratory care, Vietnam National Children’s Hospital in 2023.
Methods: Cross-sectional descriptive study was conducted on 135 children diagnosed with severe Mycoplasma pneumoniae pneumonia at the Center for pulmonology and respiratory care from May 2023 to the end of December 2023.
Results: All children were discharged from the hospital after treatment and did not have to be transferred to the Intensive Care Department. 74,8% of children with respiratory failure needed oxygen, and no child required non-invasive ventilation. 65,9% of children had to use doxycycline or quinolone, and 9,5% of children had to use corticosteroids. The average duration of fever is 9,5±6,8 days, the average hospital stay is 11,1±5,4 days. The group of children under 5 years old accounts for 72,6%, this group has respiratory failure and requires more oxygen and during treatment requires more corticoid or IVIG but is less likely to need to switch to doxycycline or quinolone than the group of children over 5 years old. year old.
Conclusion: Children with severe Mycoplasma pneumoniae pneumonia have a long hospital stay and require a combination of treatment methods. Therefore, it is necessary to diagnose and determine the severity of the disease based on clinical and paraclinical conditions for good disease management.
##plugins.themes.vojs.article.details##
Keywords
Severe pneumonia, Mycoplasma pneumoniae
References
2. Zhu Y, Luo Y, Li L et al. Immune response plays a role in Mycoplasma pneumoniae pneumonia. Front Immunol 2023;14:1189647. https://doi.org/10.3389/fmmu.2023.1189647
3. Tsai TA, Tsai CK, Kuo KC et al. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. J Microbiol Immunol Infect 2021;54(4):557-565. https://doi.org/10.1016/j.jmii.2020.10.002
4. Luo X qin, Luo J, Wang C jie et al. Clinical features of severe Mycoplasma pneumoniae pneumonia with pulmonary complications in childhood: A retrospective study. Pediatr Pulmonol 2023;58(10):2815-2822. https://doi.org/10.1002/ppul.26593
5. Choi YJ, Chung EH, Lee E et al. Clinical Characteristics of Macrolide-Refractory Mycoplasma pneumoniae Pneumonia in Korean Children: A Multicenter Retrospective Study. J Clin Med 2022;11(2):306. https://doi.org/10.3390/jcm11020306
6. Huong PLT, Hien PT, Lan NTP et al. First report on prevalence and risk factors of severe atypical pneumonia in Vietnamese children aged 1–15 years. BMC Public Health 2014;14:1304. https://doi.org/10.1186/1471-2458-14-1304
7. Lê Thị Hồng Hanh, Đặng Mai Liên, Phùng Thị Bích Thủy. Nghiên cứu một số đặc điểm lâm sàng, cận lâm sàng và nhận xét kết quả điều trị bằng macrolid ở bệnh nhi viêm phổi do Mycoplasma Pneumonia có gen kháng Macrolid. Tạp chí Nghiên cứu và Thực hành Nhi khoa 2021;5(3).
8. Bradley JS, Byington CL, Shah SS et al. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011;53(7):617-630. https://doi.org/10.1093/cid/cir625
9. Li L, Guo R, Zou Y et al. Construction and Validation of a Nomogram Model to Predict the Severity of Mycoplasma pneumoniae Pneumonia in Children. J Inflamm Res 2024;17:1183-1191. https://doi.org/10.2147/JIR.S447569
10. Lee KL, Lee CM, Yang TL et al. Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010-2019. J Formos Med Assoc 2021;120(1Pt 1):281-291. https://doi.org/10.1016/j.jfma.2020.08.018
11. Wang X, He H, Zheng J et al. A comparison of efcacy and safety of complementary and alternative therapies for severe mycoplasma pneumonia in children. Medicine (Baltimore) 2021;100(7):e23959. https://doi.org/10.1097/md.0000000000023959
12. Liu J, He R, Zhang X et al. Clinical features and “early” corticosteroid treatment outcome of pediatric mycoplasma pneumoniae pneumonia. Front Cell Infect Microbiol 2023;13:1135228. https://doi.org/10.3389/fcimb.2023.1135228